William Blair sets Harrow Health stock to Outperform

William Blair initiated coverage on Harrow Health (HROW) with an Outperform rating and a $63 fair-value estimate, citing the company's successful transition from compounding pharmacy to branded ophthalmology pharmaceutical company. Harrow's revenue grew 53.5% in the last year, driven by products like Vevye for dry eye disease, though recent Q1 2025 results missed revenue and EPS expectations despite a 38% year-over-year revenue increase. H.C. Wainwright maintained a Buy rating, raising the price target to $60, anticipating continued growth from Vevye and other products, while Harrow Health management remains optimistic about achieving its 2025 revenue guidance of over $280 million.

Analysis

William Blair's recent initiation of coverage on Harrow Health (NASDAQ:HROW) with an Outperform rating and a $63 fair-value estimate highlights the market's positive view on the company's strategic pivot from a compounding pharmacy to a branded ophthalmology pharmaceutical business. This transition is underpinned by a significant 53.5% year-over-year revenue growth and a strong gross margin of 74.5% in the last twelve months, reflecting the potential of its acquired branded products. The lead product, Vevye, for dry eye disease, has shown robust adoption and refill rates since its January 2024 launch, significantly boosted by the "Vevye Access for All" program, which quadrupled prescribers. Alongside Vevye, products like Iheezo and the re-launched Triesence are expected to drive growth in the retinal procedure segment. Despite this positive trajectory and a 38% year-over-year revenue increase to $47.8 million in Q1 2025, Harrow Health missed revenue projections of $61.13 million and reported a net loss of $0.50 per share, substantially below the expected EPS of $0.06. Nevertheless, management reaffirmed its 2025 revenue guidance of over $280 million, supported by strong sequential growth in the Vevi product line and an observed Q2 2025 demand uptick. Analyst sentiment remains largely positive, with H.C. Wainwright maintaining a 'Buy' rating and raising its price target to $60, anticipating Vevye to be a key growth catalyst.

Key Decisions for Investors

• Investors should weigh the compelling growth narrative, driven by Harrow Health's strategic shift and promising ophthalmology product pipeline, against the recent Q1 2025 revenue and earnings miss.
• Monitor the company's execution in upcoming quarters, particularly its ability to meet the reaffirmed 2025 revenue guidance of over $280 million and improve profitability, to validate the optimistic outlook.
• Given the stock's near 70% appreciation over the past year and current analyst price targets ranging from $42 to $65, prospective and current investors should carefully evaluate the risk-reward profile, considering both the strong market adoption of key products like Vevye and the recent financial underperformance.